The benefits of adjuvant systemic therapy in the treatment of early breast cancer are well established. However, many questions remain regarding the appropriate selection of patients and regimens, duration of treatment, timing or sequencing of treatment as well as the role of high-dose chemotherapy or new active drugs such as paclitaxel. Future answers will only come through continued participation in carefully designed clinical research.
|Original language||English (US)|
|Number of pages||3|
|Journal||The Nebraska medical journal|
|State||Published - Mar 1996|
ASJC Scopus subject areas